Literature DB >> 18760752

Anemia and cardiovascular risk in the patient with kidney disease.

Steven Fishbane1.   

Abstract

Patients with chronic kidney disease (CKD) often experience anemia, which causes fatigue and diminished quality of life. In addition, anemia in CKD has been associated with increased risk for cardiovascular events and left ventricular hypertrophy. To the extent that anemia plays a causal role in these relationships, treatment with erythropoiesis-stimulating agents (ESAs) could potentially help improve outcomes. To date, however, results from interventional studies have been disappointing in this regard. This article reviews the relationship between anemia in CKD and cardiovascular risk and explores current knowledge on ESA treatment.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18760752     DOI： 10.1016/j.hfc.2008.03.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN： 1551-7136            Impact factor:   3.179


  9 in total

1.  Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Authors:  Stefan Heidenreich; Frank Leistikow; Stefan Zinn; Jörg Baumann; Andreas Atzeni; Vitomir Bajeski; Jörn Dietzmann; Gert-Peter Dragoun
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

2.  Regional Cerebral Blood Flow in Children and Young Adults with Chronic Kidney Disease.

Authors:  Hua-Shan Liu; Erum A Hartung; Abbas F Jawad; Jeffrey B Ware; Nina Laney; Allison M Port; Ruben C Gur; Stephen R Hooper; Jerilynn Radcliffe; Susan L Furth; John A Detre
Journal:  Radiology       Date:  2018-06-12       Impact factor: 11.105

3.  Anaemia, haemoglobin level and cause-specific mortality in people with and without diabetes.

Authors:  Andre Pascal Kengne; Sébastien Czernichow; Mark Hamer; G David Batty; Emmanuel Stamatakis
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

4.  Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria.

Authors:  Bala Waziri; Monica Mabayoje; Babawale Bello
Journal:  Clin Kidney J       Date:  2016-07-21

5.  Shortcoming of Measuring Patient Satisfaction's Association With Anemia-Based Cardiovascular Risk in End-Stage Kidney Disease Patients.

Authors:  Hoda Abdolmonem Ahmad; Dixon Thomas; Maryam Alrais; Aaron Burton; Rajaram Jagdale
Journal:  Cardiol Res       Date:  2021-12-08

Review 6.  Cardiovascular Risk after Kidney Transplantation: Causes and Current Approaches to a Relevant Burden.

Authors:  Francesco Reggiani; Gabriella Moroni; Claudio Ponticelli
Journal:  J Pers Med       Date:  2022-07-23

7.  Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study.

Authors:  Klemens Budde; Thomas Rath; Volker Kliem
Journal:  J Transplant       Date:  2014-05-04

8.  Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Authors:  Nan Chen; Jiaqi Qian; Jianghua Chen; Xueqing Yu; Changlin Mei; Chuanming Hao; Gengru Jiang; Hongli Lin; Xinzhou Zhang; Li Zuo; Qiang He; Ping Fu; Xuemei Li; Dalvin Ni; Stefan Hemmerich; Cameron Liu; Lynda Szczech; Anatole Besarab; Thomas B Neff; Kin-Hung Peony Yu; Frank H Valone
Journal:  Nephrol Dial Transplant       Date:  2017-08-01       Impact factor: 5.992

9.  Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.

Authors:  Daniel W Coyne; Hem N Singh; William T Smith; Ana Carolina Giuseppi; Jamie N Connarn; Matthew L Sherman; Frank Dellanna; Hartmut H Malluche; Keith A Hruska
Journal:  Kidney Int Rep       Date:  2019-08-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.